TY - JOUR T1 - Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine JF - medRxiv DO - 10.1101/2021.07.15.21260362 SP - 2021.07.15.21260362 AU - Tamás Ferenci AU - Balázs Sarkadi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/29/2021.07.15.21260362.abstract N2 - Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries.Methods Virus neutralizing antibody titres, as a rapidly available but highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of the second dose of the vaccine.Findings Sex and time since the second dose had little association with the antibody titres. Age, however, was highly relevant: measurable antibody levels were present in about 90% of individuals below the age of 50, but antibody production after BBIBP-CorV vaccination was strongly reduced with increasing age. A large number of elderly subjects, reaching 25% at 60 years, and up to 50% at ages over 80, were found not to produce any protective antibody.Interpretation Neutralizing antibody titre, as a correlate of protection for COVID-19 disease susceptibility, should help to evaluate the effectiveness of the BBIBP-CorV vaccine. Results suggest that proper measures should be undertaken to prevent a potential outbreak of COVID-19 in BBIBP-CorV vaccinated but eventually unprotected elderly individuals.Funding No specific funding was used to carry out the study.Evidence before this study The BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine was found to be effective, but the Phase 3 trial included few women, almost no elderly subject and no subject with preexisting medical condition. It is therefore especially important to monitor the real-world effectiveness of this vaccine, however when searching Pubmed for (Sinopharm OR BBIBP-CorV) AND vaccine AND (effectiveness OR efficacy OR antibody OR titre) in text words with no language or date restriction and with translation of the terms enabled, we found no such published study. The most rapid way to generate such evidence is the assessment of antibody response which was found to be highly predictive for disease susceptibility. This is of crucial importance as the vaccine is approved in more than 50 countries, and hundreds of millions have already been vaccinated with many planned to be vaccinated in the near future with this vaccine.Added value of this study Virus neutralizing antibody titres were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of the second dose of the vaccine. We found that sex and time since the second dose had little association with the antibody titres. Age, however, was highly relevant: while the vast majority of those below 50 years had measurable antibody levels, this rate quickly dropped with increasing age. In subjects aged 60 years, quarter, in those above 80 almost half had no detectable neutralizing antibody.Implications of all the available evidence The real-world effectiveness of the BBIBP-CorV vaccine should be carefully monitored. Elderly subjects are especially prone to produce no protective antibody after vaccination. This should be monitored, and proper measures should be undertaken to prevent a potential outbreak of COVID-19 in BBIBP-CorV vaccinated but eventually unprotected elderly individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was used to carry out the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Used data were openly available to the public before the initiation of the study, as documented in the Data Sharing section.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified individual patient level data is openly available to the public. Together with the full analysis script it can be found at https://github.com/tamas-ferenci/SinopharmAntibodyResponse. https://github.com/tamas-ferenci/SinopharmAntibodyResponse ER -